NeoGenomics, Inc (NASDAQ:NEO) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Vishal Sikri - President, Advanced Diagnostics Warren Stone - President, Clinical Services Melody Harris - President, Enterprise Operations Conference Call Participants Dan Brennan - TD Cowen Alex Nowak - Craig-Hallum Capital Group David Delahunt - Goldman Sachs Mark Massa ...

2 This presentation contains financial measures, such as adjusted EBITDA, adjusted gross margin and adjusted net income, which are considered non-GAAP financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). Adjusted EBITDA, adjusted gross margin and adjusted net inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9490 NeoGenomics Way, Fort Myers, ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NE ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Puneet Souda - SVB Securities David Westenberg - Piper Sandler Dan Brennan - TD Cowen Andrew Brackmann - William Blair David Delahunt - Goldman Sachs ...

2 1st Quarter Clinical Services Revenue per Test • 8th Consecutive Quarter of Revenue per Test Growth • Revenue per Test Increased 8% over Prior Year to $402 • Focused on Higher-Value Tests • Positive Contributions from Strategic Reimbursement Initiatives Q2 Q3 Q4 Q1 • Gross Margin Improved 620 bps, representing the Third Consecutive Quarter of 500 bps+ of Improvement • Revenue: Highest Revenue Growth by Quarter Since Q2 of 2021. Drivers are increases in revenue per test, volume and Pharma Services revenue. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdictio ...

NeoGenomics, Inc. (NASDAQ:NEO) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Alex Nowak - Craig-Hallum Mark Massaro - BTIG Andrew Brackmann - William Blair Puneet Souda - SVB Securities Tejas Savant - Morga ...

Sequential Improvement in Revenue Growth, • Adjusted EBITDA. Improved $8.6 million versus prior year due to improvement in gross profit and lower operating expenses. Balance Sheet In $Millions Dec-22 Sep-22 Total Assets 1,740.0 1,755.6 Accounts payable and other current liabilities 83.3 78.5 Current portion of equipment financing obligations 0.1 0.1 Current portion of operating lease liabilities 6.6 6.4 Total stockholders' equity 998.0 1,013.0 • Financial Flexibility to Make Needed Investments to Drive Long ...

Saving lives by improving patient care. 3 rd Quarter 2022 Earnings Results November 8th, 2022 1 2 Forward looking statement This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorpora ...